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Abstract  
Objectives 
A recent international study reported a higher prevalence of esophageal atresia with or without 
tracheo-esophageal fistula (EA±TEF) in Western Australia (WA). The aim of this study was to 
examine the prevalence and trends of EA and/or TEF in WA; determine the proportion of cases 
with associated anomalies; and explore the impact of time of diagnosis. 
Methods 
The study population comprised all infants born in WA, 1980-2009 and registered with EA and/or 
TEF on the WA Register of Developmental Anomalies (WARDA).  
Results 
EA±TEF and TEF alone affect, on average, 1 in every 2,927 births in WA, with a total prevalence 
of 3.00 and 0.42 per 10,000 births, respectively. The prevalence of EA±TEF increased by 2.0% per 
annum, with only cases with associated anomalies (64% of cases) demonstrating an increase. TEF 
rates were stable. Among EA±TEF infants, the proportion of live births, stillbirths and elective 
terminations of pregnancy for fetal anomaly (TOPFA) was 79%, 6% and 15%, respectively; while 
the majority (94%) of TEF only cases were live births. In 2000-2009 there was 30% fall in EA±TEF 
live births with 61 (58%) cases diagnosed in first week of life, 10 (9%) prenatally and 34 (32%) at 
postmortem only. 
Conclusions 
A higher prevalence of EA±TEF in WA was observed with increase over time attributable to 
increase with associated anomalies. Consistent reporting, availability of prenatal diagnosis and 
ascertainment of cases following TOPFA or postmortem examinations can significantly affect 
prevalence of EA and/or TEF.  
Keywords 
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INTRODUCTION 
Esophageal atresia and tracheo-esophageal fistula are the most common anomalies of the esophagus 
and trachea. Esophageal atresia is a congenital anomaly of the upper gastrointestinal tract 
characterized by the complete discontinuity of the esophagus with or without an abnormal 
connection between the esophagus and the trachea (EA±TEF). Tracheo-esophageal fistula (TEF) 
can also occur without esophageal atresia and accounts for 7-18% of all congenital tracheo-
esophageal malformations.1-5  Infants are diagnosed either prenatally or, in most cases, at birth and 
require surgical repair in the first few days of life. The etiology of EA and/or TEF is still unclear 
and is considered to be multifactorial.2 3 6 7  
 
Large variations in prevalence of EA±TEF across different geographical regions have been 
reported, although no changes in prevalence over time have been observed. The overall prevalence 
of EA±TEF in 23 European registries of congenital anomalies during 1987-2006 was 2.43 per 
10,000 births, ranging from 1.27 to 4.55, with no differences in the prevalence over time.8  The 
estimated national prevalence of EA±TEF reported by the US National Birth Defects Prevention 
Network, based on data from 14 population-based birth defects registries, was 2.17 per 10,000 
births for the period from 2004 to 2006.9 For this study, cases included EA and/or TEF and 
esophageal stenosis. Similarly, a recent international study among 18 birth defects surveillance 
programs in Europe, the Americas and Australia reported an overall prevalence of EA±TEF of 1 in 
4,099 (2.44 per 10,000) births.10 Although there was no evidence of a significant linear trend among 
any of the member programs, there was both a higher prevalence, particularly of TEF alone, and 
increase in cases in Western Australia during the period of study, 1998 to 2007.  
 
Several factors may influence reporting and registration of congenital anomalies including: 
screening policies and procedures, clinician skills, timing of fetal anomaly screening, subsequent 
availability and timing of elective termination of pregnancy, and autopsy policies.11 Thus, a number 
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of factors may explain the higher observed rates of EA and/or TEF in Western Australia; including 
multiple sources of notification, inclusion of cases following termination of pregnancy or post-
mortem examinations, availability of prenatal diagnosis and higher age of registration up to six 
years.11-13 Only tabulated data were available for the international study. Individual information 
regarding timing and age of diagnosis, specific source of notification, whether cases were isolated 
or associated with multiple anomalies and whether there have been changes in diagnosis and 
reporting over time would provide further insight regarding ascertainment and reporting of cases, 
and possibly the underlying etiology of these conditions. 
 
The frequency of additional anomalies in previous population-based investigations reporting EA 
and/or TEF have ranged between 43 and 63%.1 4 5 8 14-19  Congenital heart disease is the most 
commonly associated congenital anomaly and the proportion reported with chromosomal anomalies 
is 5-10%.1 4 8 14-20  EA and/or TEF are more likely to be diagnosed in conjunction with many 
syndromes, sequences and associations; with the most common being VACTERL association.19  
 
The aim of this study was to examine the birth prevalence and trends of EA and/or TEF in Western 
Australia; determine the proportion of cases with isolated and multiple anomalies; and explore the 
impact of different sources and timing of diagnosis on rates. 
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METHODS 
Western Australia is a geographically well defined area, with a population of 2.3 million, the 
majority of whom live in the Perth metropolitan area. There are approximately 31,000 births per 
year. Cases of EA and/or TEF were identified from the Western Australian Register of 
Developmental Anomalies (WARDA), a population-based notification system of malformations 
established in 1980.11 The WARDA draws on multiple sources of notification including hospitals 
and private practitioners, Western Australian Department of Health databases (midwives’, mortality 
and hospital morbidity systems) and investigative and treatment centers. All fetuses and neonates 
diagnosed with EA and/or TEF in Western Australia from January 1980 to December 2009 
inclusive, were identified from the WARDA, including stillbirths of 20 weeks’ gestation or more, 
terminations of pregnancies for fetal anomaly of any gestation (TOPFA) and live born children up 
to six years of age. Timing and age of diagnosis was also identified and may have been prenatally 
from antenatal ultrasound, in first few weeks of life or later or at post mortem. 
 
Each individual birth defect is coded by the WARDA according to the British Paediatric 
Association International Classification of Diseases, 9th revision system (BPA-ICD9), with up to ten 
diagnostic categories available to allow coding of multiple anomalies per case. The following codes 
were used to identify the diagnosis of EA: 750.30, EA+TEF: 750.31; and TEF alone: 750.32. All 
records were reviewed and classified into one of four groups as: 1) isolated cases, if EA±TEF or 
TEF alone were the only defects present; 2) cases with non-syndromic multiple congenital 
anomalies when one or more additional non-esophageal malformations were recognized; 3) cases 
with non-chromosomal recognized conditions including syndrome, sequence, association and 
spectrum disorders; and 4) cases with chromosomal anomalies. Congenital anomalies in cases with 
non-syndromic multiple anomalies were also classified by organ system. 
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Total birth prevalence (and 95% confidence interval) and trends over time of EA±TEF and TEF, 
and by birth outcome and age at diagnosis were examined. Birth prevalence was defined as the total 
number of cases among live births, stillbirths and TOPFA divided by the sum of live births and 
stillbirths in the Western Australia population and expressed per 10,000 births. Denominator data 
were obtained from the Western Australia Department of Health and consisted of all live births and 
stillbirths of 20 weeks’ gestation or more born in Western Australia. Annual, decade-specific (1980-
1989, 1990-99, 2000-2009) and overall prevalence were calculated. The Cochran-Armitage test21  
was used to evaluate homogeneity and time trend in prevalence for EA±TEF and TEF alone, in both 
isolated cases and cases with associated anomalies. To allow for rare events and variation in births 
over time, Poisson regression with an offset term was used to assess the trend and calculate the 
average annual change in prevalence over the study period. Prevalence was also examined by birth 
outcomes classified as live births, stillbirth or TOPFA; and age at first diagnosis (prenatal, within 
first week of life, after first week of life, postmortem). Statistical analyses were performed using 
Stata 11.2 (Stata Corporation, College Station, TX). Ethics approval for access to data and to 
conduct the study was obtained from the Western Australian Department of Health Human 
Research Ethics Committee. 
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RESULTS 
A total of 260 cases of EA and/or TEF were notified to the WARDA out of 761,247 births in the 
30-year period from 1980-2009, yielding an overall prevalence of 3.42 cases per 10,000 births 
(95%CI 3.01-3.86). Annual number of births increased from approximately 21,000 in 1980 to 
31,000 in 2009. Of the 228 EA±TEF cases (3.00 per 10,000 births; 95%CI 2.62-3.41), EA with TEF 
comprised 202 (89%) of the cases and 26 (11%) had EA without TEF. The percentage of EA alone 
decreased over the three decades (14.8%, 9.8%, and 10.4% for 1980-1989, 1990-1999 and 2000-
2009, respectively). The proportion and trend in the prevalence of EA+TEF increased, on average, 
by 2.0% per year (95%CI 1.0-4.0%, P<0.01) from 2.23 (95%CI 1.66-2.92) to 2.16 (95%CI 1.63-
2.81) to 3.48 per 10,000 births (95%CI 2.82-4.26) over the three decades, respectively (Figure 1).  
 
There were 32 cases of TEF alone identified in Western Australia, 1980-2009 resulting in a 
prevalence of 0.42 per 10,000 births (95%CI 0.29-0.59). Despite the small numbers, the trend in the 
prevalence of TEF alone was relatively stable over time (P=0.98) (Figure 1).  
 
Among the 228 cases of EA±TEF, 180 resulted in a live birth (79%, 2.36 per 10,000 births), 14 
(6%) were stillbirths and 34 (15%) were TOPFA. Over the three decades, the proportion of 
livebirths decreased by a third to 66%, while in 2000-2009, 9% of cases diagnosed were stillbirths 
and almost a quarter (24%) were TOPFA. In contrast, the majority of cases of TEF alone were 
livebirths (n=30, 94%).  
 
In 2000-2009, there were 60 (63%) cases of EA+TEF cases diagnosed in the first week of life, most 
of them at birth. In 7 cases (7%) the diagnosis was made prenatally, in 1 case (1%) after the first 
week of life, and in 27 cases (28%) the diagnosis was first made postmortem (Table 1). In contrast, 
two-thirds (64%) of EA alone were first diagnosed at postmortem. Table 1 highlights the increase in 
prenatal detection and post mortem diagnoses for EA±TEF cases over the study period, with a 
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corresponding decrease in the proportion of cases diagnosed in first week of life. During 2000-
2009, the majority (82%) of TEF only cases were diagnosed in first week of life, 9% prenatally and 
9% after the first week.  
 
Only one-third (n=72, 36%) of EA+TEF cases were isolated and the remaining 130 had associated 
anomalies; including 21 (10%) with chromosomal abnormalities, 50 (25%) had non-chromosomal 
recognized conditions, of which 40 (20%) were diagnosed with VACTERL association, and 59 
(29%) had non-syndromic multiple congenital anomalies (Table 2). The most common additional 
structural anomalies were those of the cardiovascular and musculoskeletal system, present in 17.8% 
and 11.4% of cases, respectively. Infants diagnosed with EA alone had a similar proportion of non-
syndromic and non-chromosomal conditions, but a lower proportion were isolated (19%) and a 
higher percentage were diagnosed with chromosomal anomalies (n=6, 23%), but numbers were 
small (Table 2). Of the 32 cases of TEF alone, 17 were isolated (53%), 6 (19%) had multiple 
anomalies and 7 (22%) had a VACTERL association (Table 2). 
 
For all cases of EA±TEF, the total prevalence of isolated cases was 1.01 per 10,000 births (95%CI 
0.80-1.26); increasing slightly from 1.03 (95%CI 0.66-1.53) in 1980-89 to 1.25 per 10,000 births 
(95%CI 0.86-1.74) in 2000-09 (P=0.17) (Figure 2). For cases with associated anomalies the overall 
prevalence was 1.98 (95%CI 1.68-2.33) per 10,000 births; increasing, on average, by 3.0% per 
annum (P<0.01) from 1.58 (95%CI 1.12-2.18) to 1.65 (95% CI 1.19-2.23), and 2.64 per 10,000 
(95%CI 2.07-3.32) over the study decades (Figure 2). Overall, the ratio of isolated to associated 
anomalies did not vary significantly or show a trend across the three time periods (ratio 0.65 in 
1980-89, 0.45 in 1990-99, and 0.47 in 2000-09). 
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DISCUSSION 
EA±TEF and TEF alone affect, on average, 1 in every 2,927 births in Western Australia, with a 
total prevalence of 3.00 for EA±TEF and 0.42 for TEF alone per 10,000 births. The prevalence of 
EA±TEF in Western Australia has increased by 2% per annum over the 30-year period, from 1980 
through 2009. However, when cases were subdivided by isolated and associated anomalies, only the 
associated EA±TEF group demonstrated a significant increase. Furthermore, results reveal that 
there was a 30% fall in live birth cases offset by an increase in the proportion of cases diagnosed 
following stillbirth or TOPFA.    
 
In this study we found a higher prevalence of EA±TEF (3.42 per 10,000) compared to that reported 
in three recent studies; of 2.44 per 10,000 births by the International Clearinghouse for Birth 
Defects Surveillance and Research (ICBDSR),10 2.46 per 10,000 births by EUROCAT, the 
European surveillance of congenital anomalies8 and 2.17 per 10,000 births by the National Birth 
Defects Prevention Network in the US.9 Findings suggest increased case ascertainment in Western 
Australia with additional information obtained from post mortem reports most likely to explain 
higher rates. The prevalence reported in this study is also higher than that reported for Western 
Australia in the ICBDSR study (2.63 per 10,000 births)10 and is due to a misclassification of TEF 
alone, which were identified on post mortem to also have EA. 
 
Our findings reveal one-quarter of EA±TEF and TEF to be associated with non-chromosomal 
recognized conditions, considerably higher than rates of around 7-17% found in previous studies.4 8  
The most common associated anomaly was VACTERL association which was present in about 20% 
of cases, with the percentage the same in patients with EA±TEF and TEF alone. The reported 
percentage of VACTERL association in patient with EA and/or TEF in population-based studies 
varies, ranging from 2-10%,4 8 19 however, studies from single institutions report either a similar 
percentage to our finding22 or higher.23  
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Although we found an increasing prevalence of EA±TEF over the 30-year period, 1980-2009, this 
trend was observed in non-isolated cases only. No overall change in trends was observed in the 
EUROCAT study during 1987-20068 or the ICBDSR study for 1998-2007.10 Our results suggest 
that the causative factors are due to either increased reporting and ascertainment; or attributable to 
underlying etiological factors affecting embryonic fetal development more generally and are not 
just restricted to the gastrointestinal system. An increase in ascertainment of cases over time may be 
one factor contributing to both the higher proportion of and rising trend of EA±TEF with associated 
anomalies. However, given the WARDA has multiple sources of notification with no major change 
in data collection or registration of cases over the last 30 years; and that esophageal anomalies are a 
serious condition, diagnosed early in life, it is unlikely these cases will be missed, and increasing 
trends may be real.  
 
Findings highlight increasing proportion of cases diagnosed following termination of pregnancy for 
fetal anomaly and following post mortem resulting from improved availability, ascertainment and 
reporting of these occurrences. Previous studies have shown that the rate of termination of 
pregnancy is higher for cases with chromosomal or additional congenital anomalies than for cases 
with an isolated anomaly.12 Increases in the prevalence of chromosomal and syndromic anomalies 
diagnosed over the last few decades may be a result of increased detection and reporting in Western 
Australia with higher proportion of all types of associated anomalies; including chromosomal, non-
chromosomal and non-syndromic anomalies diagnosed compared with previous reports.1 4 8 14-20  
This is also affirmed by our finding of higher rates of stillbirths and terminations of pregnancies 
among cases, which are more likely to occur among those with associated anomalies and 
availability of ascertainment via prenatal diagnosis, postmortem assessment and ample period of 
follow-up.24 In addition, the WARDA also assign age at diagnosis for each specific anomaly 
diagnosed in each infant compared with other studies that classify an overall or first time of 
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diagnosis. For example, those cases terminated for chromosomal anomaly will have that specific 
anomaly diagnosed prenatally; while an esophageal anomaly diagnosed post mortem will be 
assigned as such. This may explain our higher proportion of cases diagnosed post mortem (20%) 
and fewer prenatally (8%) compared with EUROCAT study reporting a 33% prenatal detection 
rate.8 
 
An increase in underlying etiological factors associated with chromosomal and non-chromosomal 
syndromes or associations, in general, may also be implicated. Potential factors attributed to their 
rise have also been linked with increased risk of esophageal defects and include older maternal 
age,16 25  maternal medical conditions,26-28 and multiple pregnancies. Of interest is a recent study 
demonstrating a consistent association between pre-gestational diabetes and cases with esophageal 
defects and associated congenital anomalies, irrespective of maternal BMI.27 Greater use of assisted 
reproductive technology (ART) over the last 20 years may have also contributed to the increasing 
prevalence. ART is associated with increased risk of birth defects compared with births from 
spontaneous conception.29-34  
 
Due to limited data, we were unable to explore the association and contribution of these and other 
parental, genetic and environmental factors to rates and trends of EA±TEF in Western Australia, all 
of which require thorough assessment in future studies. Despite the increase in associated 
anomalies, we found the ratio of isolated to associated anomalies (~0.45) did not change over the 
last 20 years. An unequal distribution in esophageal defects was previously reported3 35 36 but not in 
the study by Torfs et al,4 where the proportion of associated anomalies didn't vary substantially 
between esophageal defects. One of the key explanations for the unequal distribution was attributed 
to delay in diagnosis.36 However, given the WARDA includes anomalies diagnosed up to the age of 
6 years, this hypothesis is not valid for this setting.11 24  
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In regards to the prevalence of TEF alone, results in the present study do not differ significantly 
from the reported prevalence in the literature. Three US studies reported the prevalence of TEF to 
be between 0.16 and 0.52 per 10,000 births,4 14 37 EUROCAT found a prevalence of 0.26 in 6 
centers,1 and the ICBDSR10 showed a total prevalence of 0.22 per 10,000 births. Although the 
Western Australian prevalence reported in the latter study was high (1.3 per 10,000 births) this has 
now dropped due to the review and additional diagnosis of EA from post mortem reports and 
reclassification of cases to EA±TEF. A much lower proportion of associated anomalies was also 
observed in infants with TEF without atresia.  
 
The strengths of this study are that it is a population-based study with prospective data collection 
and congenital anomalies diagnosed prenatally and up to the age of 6 years are included.11 24 The 
WARDA uses multiple sources for active case ascertainment and cases comprise anomalies 
occurring in live births, stillbirths and in pregnancies terminated because of fetal anomaly. Given 
that esophageal defects are more likely to be diagnosed in conjunction with other anomalies as 
chromosomal, syndromes, associations or multiple anomalies without a pattern,2 3 20  that may result 
in termination of pregnancy, a complete ascertainment of all terminations for fetal anomaly as well 
as an accurate postmortem diagnosis is also necessary to provide reliable baseline data on the 
prevalence of esophageal defects. This comprehensive approach is demonstrated when comparing 
our prevalence of EA±TEF (3.42) with that from a recent national French study, reporting a rate of 
1.8 per 10,000 births where only live birth cases were included.13  
 
In summary, we found a higher and increasing prevalence of EA±TEF diagnosed in Western 
Australia over the last 30 years compared with studies elsewhere. Findings suggest the trend is 
attributable to an increase in the proportion of infants with associated anomalies, particularly 
chromosomal and non-chromosomal cases with an association or syndrome. Separating effects of 
increased prevalence attributable to improved reporting and ascertainment of associated anomalies 
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and underlying etiological factors is difficult, but important. Future studies disentangling and taking 
these factors into account are essential to contribute to our understanding of the underlying etiology 
and impact of esophageal anomalies.  
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Figure legend 
 
Figure 1 - Prevalence of esophageal atresia without (EA) or with tracheo-esophageal fistula 
(EA+TEF) and tracheo-esophageal fistula without esophageal atresia (TEF), Western Australia, 
1980-2009 
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Figure 2 - Prevalence of cases with associated anomalies and isolated cases of esophageal atresia 
with or without tracheo-esophageal fistula in Western Australia, 1980-2009 
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Table 1: Number (%) of cases of esophageal atresia without (EA) or with tracheo-esophageal 
fistula (EA+TEF) and tracheo-esophageal fistula without esophageal atresia (TEF) in Western 
Australia, 1980-2009 by age at diagnosis 
 
Age at diagnosis 
EA (N=26)  EA+TEF (N=202)  TEF (N=32) 
1980-89  1990-99 2000-09   1980-89 1990-99 2000-09   
1980-
89 
1990-
99 
2000-
09 
  n (%) n (%) n (%)  n (%) n (%) n (%)  n (%) n (%) n (%) 
Prenatally 0 (0) 1 (17%) 3 (27%)  3 (6%) 2 (4%) 7 (7%)  1 (13%) 2 (15%) 1 (9%) 
Within the first week of life 7 (78%) 3 (50%) 1 (9%)  47 (90%) 42 (76%) 60 (63%)  5 (63%) 9 (69%) 9 (82%) 
After the first week of life 1 (11%) 0 (0) 0 (0)  0 (0) 0 (0) 1 (1%)  2 (25%) 1 (8%) 1 (9%) 
At post-mortem examination 1 (11%) 2 (33%) 7 (64%)  2 (4%) 11 (20%) 27 (28%)  0 (0) 1 (8%) 0 (0) 
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Table 2: Classification of esophageal atresia without (EA) or with tracheo-esophageal fistula 
(EA+TEF) and tracheo-esophageal fistula without esophageal atresia (TEF) cases, Western 
Australia, 1980-2009         
  
EA (n=26)   EA+TEF (n=202)   TEF (n=32) 
n % 95% CI  n % 95% CI  n % 95% CI 
Isolated  5 19.2 (8.5-37.9)  72 35.6 (29.4-42.5)  17 53.1 (36.4-69.1) 
              
Non-syndromic associated anomalies (*) 8 30.8 (16.5-50.0)  59 29.2 (23.4-35.8)  6 18.8 (8.9-35.3) 
Cardiovascular  3 11.5 (4.0-29.0)  36 17.8 (13.2-23.7)  4 1.8 (5.0-28.1) 
Digestive 3 11.5 (4.0-29.0)  8 4.0 (2.0-7.6)  2 0.9 (1.7-20.1) 
Genitourinary 1 3.8 (0.7-18.9)  16 7.9 (4.9-12.5)  1 0.4 (0.5-15.7) 
Musculoskeletal 5 19.2 (8.5-37.9)  23 11.4 (7.7-16.5)  0 0.0 (0.0-10.7) 
Central nervous system 2 7.7 (2.1-24.1)  6 3.0 (1.4-6.3)  0 0.0 (0.0-10.7) 
Head and face 0 0.0 (0.0-12.9)  9 4.5 (2.4-8.2)  0 0.0 (0.0-10.7) 
Respiratory system 0 0.0 (0.0-12.9)  4 2.0 (0.8-5.0)  1 0.4 (0.5-15.7) 
Other 0 0.0 (0.0-12.9)  5 2.5 (1.1-5.7)  1 0.4 (0.5-15.7) 
              
Non-chromosomal recognized conditions 7 26.9 (13.7-46.1)  50 24.8 (19.3-31.1)  7 21.9 (11.0-38.7) 
Vacterl association 4 15.4 (6.1-33.5)  40 19.8 (14.9-25.8)  7 21.9 (11.0-38.7) 
Oculo-auriculo-vertebral spectrum 0 0.0 (0.0-12.9)  1 0.5 (0.09-2.7)  0 0.0 (0.0-10.7) 
Caudal dysplasia 0 0.0 (0.0-12.9)  3 1.5 (0.5-4.3)  0 0.0 (0.0-10.7) 
Prune-belly sequence 1 3.8 (0.7-18.9)  2 1.0 (0.3-3.5)  0 0.0 (0.0-10.7) 
Sirenomelia 1 3.8 (0.7-18.9)  1 0.5 (0.09-2.7)  0 0.0 (0.0-10.7) 
Charge syndrome 0 0.0 (0.0-12.9)  3 1.5 (0.5-4.3)  0 0.0 (0.0-10.7) 
Meckel Gruber syndrome 1 3.8 (0.7-18.9)  0 0.0 (0.0-1.9)  0 0.0 (0.0-10.7) 
              
Chromosomal associated malformations 6 23.1 (11.0-42.0)  21 10.4 (6.9-15.4)  2 6.3 (1.7-20.1) 
Down syndrome (Trisomy 21) 3 11.5 (4.0-29.0)  5 2.5 (1.1-5.7)  1 3.1 (0.5-15.7) 
Edward syndrome (Trisomy 18) 2 7.7 (2.1-24.1)  15 7.4 (4.5-11.9)  1 3.1 (0.5-15.7) 
Other chromosomal abnormalities 1 3.8 (0.7-18.9)  1 0.5 (0.09-2.7)  0 0.0 (0.0-10.7) 
(*) Numbers do not add to total as a case may have more than one associated congenital anomaly diagnosed   
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